




Sqi
DIAGNOSTICS

ANNUAL GENERAL MEETING

FEBRUARY 27 2019



FORWARD LOOKING STATEMENTS

This presentation may contain certain statements including, without limitation, the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “benefits”, “leading to”, “possible”, “is subject to” and other similar expressions which may constitute “forward-looking statements” within the meaning of applicable securities laws.

Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sell our products including our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business; the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits; adverse changes in general economic conditions; international risk and currency exchange fluctuations; competitor activity; technology changes; regulatory approvals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in the future.


Such statements, risks and uncertainties are detailed in the Company's ongoing filings with the securities regulatory authorities, and are available to the public at www.sedar.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

2018 IN REVIEW

Key Accomplishments for 2018 included:

- Generated recurring revenues from kits sales shipping 150 kits in Q4 2018
- Exited with quarterly kit revenue run rate of ~\$250,000/quarter
- Sale and Delivery of multiple 4 SQI platforms (+one just after year-end)
- SQI Diagnostics and Predictive Health Diagnostics Announced Launch of Revolutionary Predictive Cardiac Test
- SQI Diagnostics and Microdrop Launched Revolutionary Disease Awareness Tests for Direct-to-Consumer Market.
 - imaware Celiac detection and monitoring
- Added 3 customers (plus to just after year-end)
- Appointed Mr. Eric Zwisler to our Board of Directors who brings a wealth of healthcare market experience to the team

REVENUE TRAJECTORY SINCE FISCAL Q1 2018



- kits sales drive our business success with high margin revenue
- we have been driving consistent growth in kit sales

BLUE SKY OPPORTUNITY

BLUE SKY OPPORTUNITY						
		<i>Annualized Recurring Revenue Potential</i>				
Patient Samples tested per month		Clinical or Direct to Consumer Kits		CLIA Testing Services	=	TOTAL KIT REVENUE
	10,000 --->	\$ 2,770,000	+	\$ 2,400,000	=	\$ 5,170,000
	30,000 --->	\$ 7,480,000	+	\$ 7,200,000	=	\$ 14,680,000
2024	50,000 --->	\$ 11,220,000	+	\$ 12,000,000	=	\$ 23,220,000

Positive cash flow driven by high margin kits sales

Focus on Two Major Dx Markets

Dx Target Markets Size Estimates **2017**

Global IVD Market	\$ 59 billion
US IVD Market Total (2017)	\$ 23 billion
Addressable Segments Estimate (Autoimmune, Cardiac, Inflammatory, Respiratory, Transplant, Other)	20%
Clinical Dx Reagents (Kits) as % of Total Market	66%



6.6%
CAGR

Addressable IVD Market for Kits **\$ 3.04 billion**

Direct to Consumer Kits **\$ 350 million**

Total **\$ 3.39 billion**


North America Biopharma

Biopharma Drug Development Testing	\$ 11 billion
------------------------------------	---------------

Reagents/Kits as % of Total Market	66%
------------------------------------	-----

Key SQI Addressable Segments (biomarkers, cytokines, immunogenicity)	33%
---	-----

Addressable Biopharma **\$ 2.40 billion**



>\$5 billion
market in
North America



KEY CHALLENGE FOR 2019 – GROWING CAPACITY

We made significant progress in 2018 in terms of our commercialization goals:

- We have added customers in 2018 and early 2019
- Our biggest customer, PHD, with PULS Cardiac product has moved from using 10 kits a month in early 2018 to 30 kits per month in end of 2018, now buying 60 kits per month and forecasting 90 kits per month as we move into calendar Q2.
- We are producing celiac and rheumatoid arthritis kits for our direct to consumer customer with a total forecast of 40 kits per month, at the beginning of the product launch
- We have a number of exciting new products under development agreements and expect to launch up to 3 new products in 2019
- We expect to launch our CLIA facility and transition at least one existing customer to run their tests in this facility
- We have a robust sales pipeline that could place further pressure (the good kind) on both our development and manufacturing capacity
- We are investing in manufacturing capital to remove some bottlenecks in our current capacity

The ability of our teams at SQI to continue to deliver high quality products, systems and software to our customers is exceptional

COMMERCIAL MILESTONES FOR 2019

- Continue to Generate growth in recurring revenues from existing customers that will focus on the Diagnostics market
 - Cardiac Dx
 - Direct to Consumer
 - Transplantation and Lung Injury Diagnostics
 - Molecular / Pathogen Testing
- Significant growth in revenue with a focus on positive earnings and cash flow
- Open our CLIA lab for business with DTC and Biopharma customers
- In-License up to 2 more novel test panels with leading clinician KOLs
 - ARDS (another lung health test) and LUPUS are current targets at the term sheet stage
- Complete a prototype point of care device for Lung Transplant
- Transition PULS to a finger stick blood collection method
- Maintain high levels of customer satisfaction


5 BY 5 GROWTH STRATEGY

NEXT 5 YEARS

1. ACCELERATE OUR SUSTAINABLE REVENUE
2. EXPAND OUR PRODUCT REACH WITHIN DX CUSTOMERS – WIN REPEAT BUSINESS
3. MAINTAIN INDUSTRY-LEADING TECHNOLOGIES IN HIGH VOLUME PRODUCT MARKETS
4. LAUNCH MULTIPLE NEW PRODUCTS IN DX AND PHARMA MARKETS INCLUDING DTC & POC
5. COMMERCIALIZE PRODUCTS FOR 5 DIAGNOSTICS CUSTOMERS TO EXCEED 50K+ TESTS PER MONTH



SQI
DIAGNOSTICS



CONTACT INFORMATION:

SQI DIAGNOSTICS INC.

36 METEOR DRIVE

TORONTO, CANADA M9W 1A4

IR@SQIDIAGNOSTICS.COM

416-674-9500